Navigation Links
New hypothesis explains why drugs increase risk of heart attacks and strokes
Date:2/23/2011

CLEVELAND February 21, 2011 New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration (FDA) if the cardiovascular effects of fluid retention had been better understood. Fluid retention may explain the increased risk of heart attacks and strokes of medications such as Vioxx, Bextra, and Avandia.

The research published in Clinical Hemorheology and Microcirculation (IOS Press, ISSN 1386-0291), calculates the effects of fluid retention upon the velocity of blood flow and the turbulence of flowing blood. These calculations demonstrate that fluid retention increases the risk of heart attacks and strokes. Since numerous medications cause fluid retention, the paper's findings have implications to ensure drugs on the market are safe. The pain medications Vioxx and Bextra, and the anti-diabetic medication Avandia, cause fluid retention. Vioxx and Bextra, known as cyclo-oxygenase-2 (COX-2) inhibitors, were withdrawn from the market because of safety concerns over heart attacks and strokes, and Avandia has been suspected in some reports of increasing the risk of heart attacks.

The paper's author, Robert P. Blankfield, MD, MS, clinical professor of family medicine at Case Western Reserve University School of Medicine, and a member of the Department of Family Medicine at University Hospitals Case Medical Center, used several basic cardiovascular and hydraulic equations to demonstrate that fluid retention is detrimental for the cardiovascular system.

Fluid retention increases the likelihood that blood will flow in a turbulent manner. Turbulent blood flow accelerates atherosclerosis (hardening of the arteries), thereby increasing the risk of heart attacks and strokes. Many medications cause fluid retention, which raises blood pressure in some, but not all, individuals. Physicians worry about fluid retention if it does raise blood pressure, but are unconcerned when blood pressure is unaffected.

"This paper demonstrates that fluid retention is unhealthy because it increases the likelihood that blood will flow in a turbulent manner regardless of whether or not blood pressure is raised. Therefore, drugs that cause the body to retain fluid are dangerous for the cardiovascular system," says Dr. Blankfield.

"If the FDA had been aware of the increased cardiovascular risk that arises from drugs that cause fluid retention, Vioxx, Bextra, and Avandia might never have been approved. These findings might spur the FDA to alter some of its current policies," he continues. "The calculations in this paper might also help pharmaceutical manufacturers screen drugs for their cardiovascular risk at an early stage in the drug development process."

The cardiovascular safety problems with Avandia have prompted the FDA to require verification of cardiovascular safety for new anti-diabetic medications. It is Dr. Blankfield's opinion that this response by the FDA does not go far enough. "Based upon the calculations in the manuscript, the FDA ought to require verification of cardiovascular safety for all medications, old as well as new, that cause fluid retention," says Dr. Blankfield. Several older anti-diabetic medications cause fluid retention, including insulin and sulfonylureas (glyburide, glipizide, glimerperide). The paper suggests it would make more sense to scrutinize these older anti-diabetic medications for cardiovascular safety than to scrutinize newer anti-diabetic medications, such as saxagliptin, that do not cause fluid retention.

Additional medications currently on the market that cause fluid retention include the COX-2 inhibitor Celebrex, non-selective non-steroidal anti-inflammatory drugs (ibuprofen, known as Advil, Motrin) and some anti-seizure medications (Neurontin, Lyrica, Tegretol).

Fluid retention increases blood pressure in some individuals, increases stroke volume (the amount of blood that is ejected by the heart with each contraction) in others, and causes edema (swelling). Some blood pressure lowering medications also increase stroke volume and cause edema but prevent heart attacks and strokes when used to treat hypertension. According to Dr. Blankfield, it would make sense for drug companies to be cautious about bringing drugs to market that cause fluid retention but do not lower blood pressure.

He adds that it may be possible to reduce or neutralize the increased cardiovascular risk that occurs as a result of fluid retention simply by using a diuretic. Therefore, patients may be able to safely use medications such as Vioxx, Bextra, and Avandia if they simultaneously use a water pill.

The mathematical analysis performed by Dr. Blankfield has implications for public health and safety that extend beyond medications. Because sodium chloride (table salt) causes fluid retention, it likely increases the risk of heart attacks and strokes. Since it is a food additive, it would be appropriate for the FDA to address the danger of consuming sodium chloride. It would be possible to categorize processed foods based upon whether they have a low or high salt content. The FDA could mandate that processed foods with a high salt content be labeled with a simple warning: Based upon the amount of sodium chloride (salt) in this food, eating this product increases the risk of heart attacks and strokes.

In summary, if Dr. Blankfield's mathematical analysis accurately reflects the workings of the cardiovascular system, pharmaceutical manufacturers may be able to identify the cardiovascular risk of drugs by utilizing basic principles of hemodynamics and hydraulics; the FDA may be able to assure the cardiovascular safety of all drugs by mandating that pharmaceutical manufacturers obtain detailed data on those drugs that cause fluid retention but do not lower blood pressure; and for drugs that have beneficial effects but also cause fluid retention, it may be possible for patients to safely use these drugs if they simultaneously use a water pill.


'/>"/>

Contact: Jessica Studeny
Jessica.studeny@case.edu
216-368-4692
IOS Press
Source:Eurekalert

Related medicine news :

1. The protective brain hypothesis is confirmed
2. New studies question vascular multiple sclerosis hypothesis and treatment
3. Personal Injury Attorney David Perecman Explains the Possible Legal Consequences of Fatal 911 Operator Error in New York
4. Feedback loop explains inflammatory effect on intestinal lining
5. Book explains how focus on strengths, not failures, helps teens succeed in school
6. PCI Compliance and Data Security Requires Private Key Management – New Industry White Paper Explains
7. Drug Rehab Treatment Center Explains Rehabilitation Program Using YouTube
8. New E-Book Explains the Facts About Dental Implants
9. Brain Cell Study Explains Eureka Moment
10. Texas A&M researcher explains how embryo fights retroviral infection
11. The private sale of drugs in public hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens Commission on ... and renowned professor of psychiatry Thomas Szasz, is continuing its protest against the use ... Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent protest ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Loma Linda University ... new adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the ... Check out the event photo slidehsow. , During the program, Richard H. Hart, ...
(Date:5/24/2016)... ... , ... Backed by decades of experience, Metroloji Okulu works ... best suited solution to meet regulatory requirements. Their professional staff also performs on-site ... , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical data ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Growing in ... growing trend, more gluten-free products are available and easily accessible. Whether someone chooses to ... to cater to a certain diet, King Kullen Grocery stocks their shelves with many ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... by 9.3 million people, or 10% over last year, according to data in ... under group policies was comparatively stable, with a slight decrease in risk-based groups ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/23/2016)... 2016   Purdue Pharma L.P.  today announced ... with Egalet Corporation and Acura Pharmaceuticals, Inc. that ... the agreement the companies will exchange valuable patent ... companies to develop and sell several opioid pain ... reflects the commitment of Purdue Pharma to seek ...
Breaking Medicine Technology: